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ABSTRACT  
The TTC12-ANKK1-DRD2 gene-cluster has been implicated in adult smoking. Here, 
we investigated the contribution of individual genes in the TTC12-ANKK1-DRD2 cluster in 
smoking and their association with smoking-associated reward processing in adolescence. A 
meta-analysis of TTC12-ANKK1-DRD2 variants and self-reported smoking behaviours was 
performed in four European adolescent cohorts (N=14,084).  The minor G-allele of rs2236709, 
mapping TTC12, was associated with self-reported smoking (p=5.0x10-4) and higher plasma 
cotinine levels (p=7.0x10-5). This risk allele was linked to an increased ventral-striatal blood-
oxygen level-dependent (BOLD) response during reward anticipation (n=1,263) and with 
higher DRD2 gene expression in the striatum (p=0.013), but not with TTC12 or ANKK gene 
expression. These data suggest a role for the TTC12-ANKK1-DRD2 gene-cluster in adolescent 
smoking behaviours, provide evidence for the involvement of DRD2 in the early stages of 
addiction and support the notion that genetically-driven inter-individual differences in 
dopaminergic transmission mediate reward sensitivity and risk to smoking. 
Keywords: fMRI, genetics, IMAGEN-ALSPAC-NFBC, meta-analysis, risk taking, smoking.  
  
INTRODUCTION 
 Smoking is one of the leading causes of premature death (World Health Organization, 
2015). The majority of adult smokers (80-90%) initiate smoking during adolescence (Wittchen 
et al., 2008) and genetic factors were found to explain 44% of the individual differences (Vink 
et al., 2005). Adolescence is thus associated with an increased risk of developing long-lasting 
dependencies to nicotine and other substances (Van De Ven et al., 2010), rendering this 
developmental period critical for the investigation of genetic risk factors and the resulting 
neurobehavioral mechanisms implicated in tobacco smoking. However, our knowledge on how 
genes influence brain mechanisms in smoking is limited, and existing findings are often based 
on sample sizes not large enough to yield conclusive results (Munafo and Flint, 2011). 
Moreover, the investigation of smoking in adolescents is often hampered by reporting biases 
resulting from self-report measures (Kandel et al., 2006), thus requiring complementation by 
biologically-verified markers of nicotine use such as cotinine (Keskitalo et al., 2009). 
 Smoking in adolescence, in particular smoking initiation, is influenced by behaviours such 
as risk taking and impulsiveness, which reflect dissociation between the development of the 
subcortical reward system and a comparatively delayed maturation of cortical inhibitory 
functions characteristic for this developmental period (Lydon et al., 2014). In adult smokers 
this maturation is complete, together with the direct consequence of chronic tobacco exposure, 
resulting in a neurobehavioral context distinct from that in adolescents. This suggests that 
genetic factors and the biological processes mediating smoking behaviour may be different in 
adolescents and adults. For example in adults, it has previously shown that a gene-cluster 
containing the dopamine receptor 2 (DRD2), the ankyrin repeat and kinase domain containing 
1 (ANKK1) and the tetratricopeptide repeat domain 12 (TTC12) genes, is associated with 
tobacco smoking (Ducci et al., 2011; Gelernter et al., 2006). Similar results were found in 
adolescents with associations stronger in adolescence than in mid-adulthood (Ducci et al., 
2011). While this observation supports the notion of shifting biological processes underlying 
tobacco smoking across the life span, the mechanisms by which variations in this gene-cluster 
exert their biological effect on smoking behaviour and smoking initiation in adolescents have 
not yet been elucidated. 
 TTC12, ANKK1 and DRD2 are located in close proximity on chromosome 11 in a region 
of high linkage disequilibrium (LD). In addition to nicotine, the gene-cluster has been 
implicated in alcohol and opiate addiction (Nelson et al., 2013; Xu et al., 2004; Yang et al., 
2007), suggesting that its influence on smoking may be exerted through a mechanism which is 
not substance-specific. TTC12 encodes for the tetratricopeptide repeat domain 12 protein, 
which is implicated in dopaminergic transmission and neurodevelopment (Castelo-Branco and 
Arenas, 2006). ANKK1 is hypothesized to encode a signalling protein which mediates the 
expression of DRD2 (Huang et al., 2009). DRD2 in turn has a central role in regulating the 
dopamine reward system that mediates the reinforcing effects of all known addictive 
substances including nicotine mainly through striatal dopaminergic transmission (Sweitzer et 
al., 2012).  While other dopamine-related genes have been associated to smoking behaviours 
(Herman et al., 2014), we were interested in further investigating the role of this genetic region 
in early smoking initiation (Mayhew et al., 2000) and in characterising the molecular and 
neurological mechanisms underlying this association.  
 Specifically, we aimed (i) to identify single nucleotide polymorphisms (SNPs) in the 
TTC12-ANKK1-DRD2 gene-cluster, associated with self-reported cigarette smoking in 
adolescents through meta-analysis of smoking data from 14,084 youths and blood cotinine 
levels, an objective measure of nicotine exposure, in a subset of 2,540 youths, (ii) to 
functionally characterise relevant SNPs by measuring allele-specific gene expression in human 
post-mortem striatal brain tissue and (iii) to assess the genotype effect on reward sensitivity by 
analysing its relation with the blood-oxygen level-dependent (BOLD) response in the ventral 
striatum during reward anticipation, risk taking and tobacco smoking in a subset of adolescents 
from the IMAGEN sample (Figure 1).  
 
EXPERIMENTAL PROCEDURES 
Participants 
We included 4,512 adolescents and from the Northern Finland Birth Cohort NFBC1966 
(Sabatti et al., 2009),  4,307 derived from the NFBC1986 (Vaarasmaki et al., 2009),  3674 from 
the Avon Longitudinal Study of Parents and Children (ALSPAC) (Golding, 1990), and 1,591 
(of which 1,263 provided functional Magnetic Resonance Imaging (fMRI) and 1,085 on risk 
taking) from IMAGEN (Schumann et al., 2010). Demographic characteristics and phenotypic 
distribution of the samples are reported in Table-1.  
Smoking-related phenotypes 
Lifetime smoking, measuring the number and occasions of cigarette smoking adapted 
for adolescents who have lesser degree of exposure to smoke than adults, was self-reported in 
each cohort (see Supplementary-Material for details in each cohort; Ducci et al., 2011), and 
recoded into four categories: Never-Tried (never smoked), Ever-Tried (smoked at least once), 
Smokers (smoked more than once in the last 30 days), as previously used (Ducci et al., 2011) 
and Weekly-Smokers (smoked at least once a week in the last month). We used Never-Tried as 
our reference group to contrast with Ever-Tried, and subsequently validated our results by 
further contrasting with adolescents who smoke occasionally (Smokers) and regularly (Weekly-
Smokers).  
Genetic data  
We chose 33 SNPs based on data availability in the cohort that was genotyped first, i.e. 
NFBC1966. Not all of these 33 SNPs were available in each sample. (SNPs and LD structures 
for each sample can be found in Supplementary-Figure-1, MAF of the separated cohorts can 
be found in Supplementary Table 1). 
Cotinine level 
Plasma cotinine and genotypic data were available in n=2,540 ALSPAC participants 
(see Supplementary-Material).  
Brain genotype and gene expression  
We extracted gene expression levels of TTC12, ANKK1 and DRD2 in the striatum  from 
the GEO series GSE25219 database (Kang et al., 2011). Probe clusters assessing expression 
across the entire transcript of TTC12, ANKK1 and DRD2 were extracted (Transcript Cluster 
IDs 3349453, 3349535 and 3391653, respectively). We independently replicated the 
association between DRD2 expression levels (Transcript exon probe ID 3391671) and 
rs2236709 genotypes in 93 post-mortem cortical brain tissue samples of European ethnicity, 
SNPExpress (Heinzen et al., 2008). 
Functional MRI 
Brain activation during reward anticipation was measured using a modified monetary 
incentive delay (MID) fMRI task (Knutson et al., 2000) in a sample of 1,263 individuals from 
the IMAGEN sample. Gender, recruitment site and handedness were included as covariates. 
Based on previous findings (Yacubian et al., 2006), we focused on the ventral striatum 
(bilateral) as regions of interest (ROIs) (family-wise-error (FWE)-corrected, p<0.05) as 9-mm 
spheres from the contrast ‘anticipation of large reward > anticipation of no reward’ (±15, 9, -9 
in Montreal Neurological Institute (MNI) space) (see Supplementary-Materials for more 
details). 
Risk Taking 
We used the Cambridge Gambling Task (CGT) from the Cambridge Cognition 
Neuropsychological Test Automated Battery (CANTAB; Cambridge Cognition 
http://www.cambridgecognition.com/). 
Statistical analyses 
Genetic-association analyses and meta-analysis 
Genetic data analysis used Plink v1.07 (http://pngu.mgh.harvard.edu/~purcell/plink/) if 
not otherwise indicated. Single marker association analyses were conducted using logistic or 
linear regression (for binary or quantitative traits, respectively) (see also Supplementary-
Materials). Each genotype was coded as the number of copies of the minor allele in all cohorts. 
Analyses controlled for gender, (all samples) age and site (IMAGEN).  
Meta-analysis was performed using the meta-analysis procedure from Plink. Significant 
results after Bonferroni-correction were investigated further (see also Table-2). 
Association of genotype and BOLD responses in the ventral striatum, brain activation and risk 
taking in the IMAGEN cohort 
We carried forward the results of the confirmatory analysis to investigate associations 
with brain activation and behavioural phenotypes underlying reward processing. ANOVAs 
comparing extracted mean ventral striatum BOLD responses across genotypes for those SNPs 
showing associations to self-reported smoking and cotinine were carried out in SPSS version 
20.0 (IBM Corp., Armonk, NY). We explored associations of the smoking risk variants within 
TTC12-ANKK1-DRD2 gene-cluster with risk taking. We expected to find positive associations 
between genetic risk for smoking and risk taking and tested for this association one-tailed.  
 
 RESULTS 
 A summary of the main findings is illustrated in Figure 1.  
Meta-analysis Exploring the association between TTC12-ANKKI-DRD2 and Smoking 
Comparing adolescents who Never-Tried smoking with those who Ever-Tried across 
four cohorts, we identified a significant association with rs2236709 (Risk allele G; Odds ratio 
(OR) =1.10, 95% confidence interval (CI): 1.04-1.16, p=5.0x10-4) (Figure-2 and Table-2). The 
minor G-allele of rs2236709 was linked to increased risk for smoking amongst subgroups of 
regular smokers (Smokers vs. Never-Tried: OR=1.13, 95% CI: 1.05-1.22, p=0.001; Weekly-
Smokers vs. Never-Tried: OR=1.16, 95% CI: 1.06-1.27, p=0.001) (Figure-2B; Supplementary-
Material Tables 2 and 3). 
 
Association of cotinine level and self-reported smoking behavior 
Higher cotinine levels correlated with a higher number of self-reported cigarettes 
(Spearman's ρ=0.33, p=3.7x10-53), thus validating self-reported smoking. Mean cotinine levels 
in ng/ml (SD) for each category of smokers were: Never-Tried=0.73 (2.73), Ever-Tried=15.18 
(46.51), Smokers=28.13 (61.64) and Weekly-Smokers=64.97 (82.51). One-way ANOVA 
revealed significant difference across lifetime smoking categories (F(3,3319)=25.09, 
p=4.80x10-16, R2=0.022). Stratification of mean plasma cotinine levels according to rs2236709 
genotypes indicated a significant positive association with the minor G-allele [F(2,2537)=9.64, 
p=6.76x10-5, R2=0.003) (Figure-2C, Supplementary Table 4), thus confirming the association 
of rs2236709 with self-reported smoking. 
 
Rs2236709 influences on striatal DRD2 expression  
Rs2236709 is located within TTC12 and is in LD with the other genes in the locus, 
ANKK1 and DRD2 (see Supplementary-Material Figure-1). To investigate which of these three 
genes contributed to the effects of rs2236709 on smoking, we analysed their expression in post-
mortem human brain samples. Figure-3A shows expression of TTC12, ANKK1 and DRD2 in 
the striatum across the lifetime. It was indicated that DRD2 mRNA levels in the striatum 
increased steadily during the foetal stages and reached a peak in adolescence, while ANKK1 
and TTC12 expression levels were low overall. We performed association analyses to 
investigate the effects of rs2236709 on striatal DRD2, TTC12 and ANKK1 expression and 
included developmental stage as a covariate. The minor G-allele of rs2236709 was associated 
with increased expression of DRD2 in the striatum (r=.39, p=0.013, df=37; Figure-3B). Neither 
expression of TTC12 nor that of ANKK1 was influenced by rs2236709 genotypes (p=0.176 and 
p=0.244, respectively). There was no association of gender (p=0.627) or RNA integrity 
(p=0.296) with DRD2 gene expression. 
 As there is, to our knowledge, no other dataset contains expression levels of DRD2 in 
the striatum and rs2236709 genotype data, we independently replicated the association between 
DRD2 expression levels and rs2236709 in cortical brain tissue samples of European ethnicity 
(Heinzen et al., 2008), and found the association to be significant (puncorrected=0.003, 
pcorrected=0.049, corrected for the number of DRD2 probes). 
 
Association of rs2236709 genotype and ventral striatum BOLD response during reward 
anticipation    
As our results suggest that altered dopaminergic transmission in reward-related brain 
areas (e.g., the ventral striatum) may underlie the association of rs2236709 with smoking, we 
further measured associations of this variant with BOLD response during reward anticipation 
in the ventral striatum of 1,236 IMAGEN participants. Due to a skewed allele distribution of 
rs2236709 (nAA=706, nAG=467, nGG=90), we pooled heterozygotes and GG-homozygotes (G-
carriers) and compared them to AA-homozygotes. Our results show a significantly higher 
BOLD response in the left ventral striatum of G-carriers vs. AA-homozygotes 
[F(1,1261)=5.803, puncorrected=0.016, pcorrected=0.032, R2=0.005, Supplementary-Materials), 
indicating an association of the risk allele (G) with greater reward sensitivity and increased 
DRD2 expression. No significant associations of rs2236709 genotypes with BOLD response 
in the right ventral striatum (p=0.237) were observed. 
 
Association between Risk taking, rs2236709, and ventral striatum BOLD response during 
reward anticipation   
As we expected a positive association between genetic risk for smoking and risk taking, 
this association was tested one-tailed. Risk taking positively associated with risk allele (G) of 
rs2236709 (r=0.056, p=0.033), and ventral striatal BOLD response (left: r=0.033, p=0.112; 
right: r=0.049, p=0.034). Risk taking also significantly associated with the number of occasions 
of lifetime cigarette smoking (r=0.056, p=0.034). 
 
DISCUSSION 
 
The current study carried out a neurobehavioral characterisation of the TTC12-ANKK1-
DRD2 gene-cluster and smoking in adolescence using four large datasets from different 
European countries. Our result demonstrated that this gene-locus exerts its effect on smoking 
behaviors such as smoking initiation and frequency already in the very early stages of nicotine 
abuse. To attain a mechanistic understanding of the associations of the minor G-allele of 
rs2236709 with both increased self-reported nicotine intake and higher cotinine levels in 
adolescents, we found that the genetic risk factor rs2236709 regulates DRD2 gene expression, 
and is also associated with activation of ventral striatum during reward anticipation and risk 
taking, a behaviour associated with drug initiation.  
DRD2 is a key molecular determinant of reward sensitivity (Sweitzer et al., 2012), 
which reaches its peak expression in the striatum during adolescence. High DRD2 expression 
increases sensitivity to rewarding stimuli, thus increases sensitivity to the effects of substances 
(DiNieri et al., 2011) as well as risk taking (Cocker et al., 2012). This combination increases 
vulnerability for addictive behaviors (Leyton and Vezina, 2014). Thus, enhanced DRD2 
expression in adolescents is likely to be one component of risk for substance abuse and smoking 
in particular. Whereas DRD2 receptor availability is reduced during the compulsive stages of 
substance addiction (Johnson and Kenny, 2010), early substance use has been linked to 
increased DRD2 expression levels in the ventral striatum (Koob and Volkow, 2009), suggesting 
a differential regulation of DRD2 in adolescents experimenting with drugs compared to 
established nicotine dependence in adults.  
Our results suggest that carriers of rs2236709 G-risk allele are at a particularly high risk 
of nicotine abuse, presumably due to an allele-specific increase in DRD2 expression, in carriers 
of the G-risk allele found in human post-mortem brain tissue retrieved from the striatum. While 
our cohorts have different ancestry the LD structure of the rs2236709 locus is similar, 
suggesting that the findings in the post-mortem human brains can be extended to all our 
cohorts. Concurrently, increased ventro-striatal response during reward anticipation was 
observed in carriers of the G-risk allele in functional neuroimaging analyses of 14 year-old 
IMAGEN participants. Together these findings suggest an enhanced (ventro-)striatal 
dopaminergic activity underlying the observed association. Our cognitive findings using the 
IMAGEN sample are in keeping with this interpretation, namely that carriers of the risk allele 
showed higher risk taking behavior, which in turn was associated with increased ventral striatal 
activation and with increased nicotine use.  
We did not detect significant association between smoking frequency and ventral 
striatal activity in this sample of 14 year-old adolescents in which 72% had never smoked. This 
might be explained by insufficient exposure to cigarettes due to young age and/or reduced 
availability of cigarettes compared to older cohorts, such as NFBC1966 where only 32% 
adolescents had never smoked at that age.  
Rs2236709 is localised in the second intron of the TTC12 gene locus and tags a 
haplotype that ranges from the promoter to the third exon of the TTC12 gene. While it is 
correlated with DRD2 expression in the striatum, it is not associated with the expression of 
TTC12 itself. However, it is well known that even Cis-acting gene expression can be regulated 
by genetic variations that are not immediately adjacent to the gene they are regulating (Kirsten 
et al., 2015).  
This study has some limitations: (i) different cohorts applied different measures to 
assess smoking behaviour, which limited us from obtaining a continuous measure consistent 
across studies, but instead combined information into distinct groups. (ii) Smoking habits have 
been subject to changing societal and legal attitudes over the last decades. Data acquisition 
among the different cohorts spreads over several decades, which was not accounted for. (iii) 
Cotinine can also account for second hand smoking, moreover the half-life of cotinine being 
16-18 hr is much shorter than some of the self-reported smoking behaviours that measure 
longer tobacco use (Jarvis et al., 1988; Perez-Stable et al., 1995; Vartiainen et al., 2002). (iv) 
Genetic heterogeneity between studies should be noted as we pooled all samples of European 
ancestry due to limited data on adolescent smoking. Two cohorts (NFBC1966, NFBC1986) 
were of Finnish ancestry, and genetically distinct from the other two European cohorts 
(IMAGEN, ALSPAC), which might limit generalisation of our findings. Notably, despite some 
differences of the minor allele frequency (MAF), the direction of the smoking-risk SNP effects 
is consistent across cohorts and I2 of rs2236709 indicated no heterogeneity across cohorts.  
Our work proposes a neurobiological pathway to nicotine abuse in a developmental 
period characterized by both vulnerability to the effects of nicotine, and great therapeutic 
potential to prevent or overcome its abuse (Toumbourou et al., 2007). Noting the recent success 
of interventions targeting behavioral risk profiles (Conrod et al., 2013), our neurobehavioral 
characterization provided a basis for developing interventions targeting biological mechanisms 
underlying nicotine abuse. 
 
Table 1: Demographic characteristics and phenotypic distribution of the study samples. 
 NFBC1966 NFBC1986 ALSPAC IMAGEN 
    Whole sample fMRI sample Risk-taking sample 
Total (N) 4512 4307 3674 1591 1263 1085 
Male (in %) 47.3 47.6 51 49.6 48.9 48.9 
Age in years 14 16 15 14 14 14 
Country Finland Finland U.K 
Germany, U.K., France, 
Ireland 
Germany, U.K., France, 
Ireland 
Germany, U.K., France, 
Ireland 
Year of 
assessment 
1980 2002 2006 2008 2008 2008 
Never-Tried       
n 1436 1539 1935 1139 914 771 
% 31.83 35.73 52.67 71.59 72.40 71.10 
Ever-Tried       
n 3076 2768 1739 452 349 314 
% 68.17 64.26 47.33 28.41 27.60 28.90 
Smokers       
n 757 982 891 189 146 133 
% 16.78 22.8 24.25 11.88 11.40 12.30 
Weekly-
Smokers 
      
n 309 844 371 100 71 65 
% 6.85 19.60 10.10 6.29 5.60 6.00 
 
Notes Table 1: The total sample size N was decomposed into participants, who never tried smoking (Never-Tried) as contrasted to those who have 
tried smoking at least once (Ever-Tried); this comparison is mutually exclusive. Out of those Ever-Tried participants, smokers and weekly smokers 
were taken; percentages refer to the total sample size (N).  
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Table 2: Association between SNPs spanning the TTC12-ANKK1-DRD2 gene-cluster and smoking for Ever-Tried vs Never-Tried.  
BP Gene SNP Location MAF 
Ref allele/ N P OR 
Q I2 
Other allele Samples 
Individual
s 
(FEM) 
(REM
) 
(FEM
) 
(REM
) 
11268541
2 TTC12 rs4517559 
flanking 
5’UTR 0.3736 C/T 4 13553 0.002   1.08   
0.2
7 23.84 
11269198
6 TTC12 rs2236709 Intron 0.2588 G/A 4 14081 
0.0005
*   1.1   
0.6
6 0 
11269340
7 TTC12 rs7927508 Intron 0.3667 G/A 3 9762 0.009   1.08   
0.1
5 46.93 
11269413
3 TTC12 rs2156486 Intron 0.1814 G/T 4 13555 0.008   0.92   
0.8
3 0 
11269937
8 TTC12 rs723077 
Coding, 
Met73Leu 0.4894 C/A 3 9771 0.06   0.94   
0.6
3 0 
11270435
6 TTC12 
rs1050217
2 Intron 0.4596 T/C 4 13675 0.004   0.93   
0.1
6 41.71 
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11270591
9 TTC12 rs2303380 
Intron 
splice site 0.3819 G/A 3 9771 0.49   1.02   
0.1
8 41.76 
11271653
9 TTC12 rs2288159 Intron 0.1561 T/G 3 9768 0.13   1.06   
0.6
3 0 
11272113
3 TTC12 rs4987094 Intron 0.1004 A/G 3 9777 0.12   1.07   
0.6
7 0 
11273581
0 TTC12 rs2276070 Intron 0.1541 T/C 3 9774 0.13   1.06   
0.6
5 0 
11273988
9 TTC12 rs719802 Intron 0.3953 T/C 3 9772 0.36   1.03   
0.3
3 8.76 
11273998
5 TTC12 rs719804 Intron 0.249 G/A 3 9759 0.06   1.07   
0.7
6 0 
11274938
7 TTC12 rs2282511 
flanking 
3’UTR 0.3455 A/C 3 11764   0.11   1.08 
0.0
9 57.82 
11275434
6 TTC12 rs754672 
flanking 
3’UTR 0.4894 T/C 4 13552 0.002   0.92   
0.4
8 0 
20 
 
11276171
8 
ANKK
1 rs877138 
flanking 
5’UTR 0.3431 G/A 3 9777 0.25   1.04   
0.3
7 0 
11276858
0 
ANKK
1 rs4590907 Intron 0.1436 G/T 4 13577 0.23   1.04   
0.7
6 0 
11277203
1 
ANKK
1 rs7118900 
Coding, 
Ala239Thr 0.1896 A/G 3 9767 0.24   0.95   
0.8
8 0 
11277522
5 
ANKK
1 rs4938016 
Coding, 
Gly442Ar
g 0.4452 G/C 3 11966 0.002   1.09   0.5 0 
11277537
0 
ANKK
1 rs2734849 
Coding, 
His490Arg 0.4886 G/A 4 13580 0.01   0.94   0.3 18.9 
11277603
8 
ANKK
1 rs1800497 
Coding, 
Glu713Lys
, TaqIA 0.2026 A/G 4 13549 0.47   0.98   
0.7
1 0 
11278866
9 DRD2 rs6277 
Coding, 
Pro219Pro 
0.1220
1 A/G 3 11981 0.004   0.92   
0.5
7 0 
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11280111
9 DRD2 rs1076563 Intron 0.4127 C/A 3 9773 0.07   0.95   
0.7
8 0 
11280354
9 DRD2 rs2471857 Intron 0.1577 T/C 3 9772 0.38   0.96   0.7 0 
11281589
1 DRD2 rs7125415 Intron 
0.0991
4 T/C 3 9775 0.09   1.08   
0.4
3 0 
11281859
9 DRD2 rs4648318 Intron 0.2538 C/T 3 9768 0.02   1.08   
0.5
3 0 
11282466
2 DRD2 rs4274224 Intron 0.4823 G/A 3 9771 0.48   1.02   
0.4
2 0 
11282968
4 DRD2 rs4581480 Intron 
0.0991
9 C/T 3 9768 0.42   1.04   
0.2
8 20.71 
11283498
4 DRD2 rs7131056 Intron 0.4205 C/A 3 9762 0.14   1.05   
0.3
7 0 
11284660
1 DRD2 rs4938019 Intron 0.1447 C/T 4 13588 0.29   1.04   
0.4
1 0 
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11285216
5 DRD2 
rs1236428
3 
flanking 
5’UTR 
0.0756
3 G/A 3 9765 0.94   0.1   
0.9
8 0 
11285797
1 DRD2 
rs1089155
6 intergenic 0.1758 T/G 3 9772 0.51   1.03   
0.3
5 5.8 
11286094
6 DRD2 rs6589377 intergenic 0.3776 G/A 4 13581 0.66   1.01   
0.3
4 10.46 
11286342
1 DRD2 rs4482060 intergenic 
0.3003
2 T/A 3 11955 0.39   1.03   
0.4
8 0 
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Notes Table 2: Association between SNPs spanning the TTC12-ANKK1-DRD2 gene-cluster and self-reported smoking behaviour. Ever-Tried 
(N=8722) are compared to Never-Tried (N=6049) (binary logistic regression). Results from NFBC1966, ALSPAC, NFBC1986 and IMAGEN 
have been combined using meta-analysis. FEM=Fixed effect model, REM=Random effect model, Q=Cochrane’s Q statistic, I2=heterogeneity 
index (0-100), N=number of study samples. Significant p values are in bold, of these those that remain significant after Bonferroni correction for 
multiple testing are indicated by an asterisk. Thick lines indicate boundary between Linkage Disequilibrium blocks.  
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Figure legends: 
Figure 1: Study aims, statistical analysis strategy, and results. 
 
Figure 2: Association between 33 single nucleotide polymorphisms (SNPs) covering the 
chromosome 11q23 TTC12-ANKK1-DRD2 gene-cluster and self-reported smoking behavior in 
adolescence. Results of the meta-analyses across the NFBC1966, NFBC1986, ALSPAC and 
IMAGEN cohorts are reported. p-values were meta-p-values computed under fixed effect 
models. Given the multiple testing correction for all SNPs a significance threshold of .0015 
was used. The blue diamond indicates the most significantly associated SNP. This was 
rs2236709 with p=5.0x10-4 for Ever-Tried vs. Never-Tried, rs2236709 with p=.001 for 
Smokers vs. Never-Tried and rs2236709 with p=.001 for Weekly Smokers vs. Never-Tried. For 
other SNPs, diamonds are colored in a white-to-red scale corresponding to R2 values from 0 to 
1 with the most significant SNPs. The SNP position refers to National Center for Biotechnology 
Information build 35. Estimated recombination rates are from HapMap and gene annotations 
are from UCSC genome browser with build. (B) Forest plots for rs2236709 for the comparisons 
of the reference group (i.e. Never-Tried) with Ever-Tried, Smokers and Weekly-Smokers. Box 
areas are proportional to the weight of the individual study. The overall summary odds ratios 
(OR) computed with a fixed effect model are represented by a diamond whose width indicate 
the 95% confidence interval (CI). Results of the analyses were as follows: Ever-Tried vs. 
Never-Tried OR=1.10, 95%CI 1.04-1.16, p=.5.0x10-4; Smokers vs. Never-Tried OR=1.13, 95% 
CI 1.05-1.22, p=.001 and Weekly-Smokers vs. Never-Tried OR=1.16, 95% CI 1.06-1.27, 
p=.001 on the left, middle and right forest plots, respectively. (C, left plot) Association 
between 33 SNPs and cotinine level in the ALSPAC cohort. Blue diamond indicates the most 
significantly associated SNP (rs2236709), as determined by linear regression analyses. Other 
diamonds are color-coded in a white-to-orange scale corresponding to increasing R2 values of 
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the respective SNP with rs2236709. The SNP position refers to National Center for 
Biotechnology Information build 35. Estimated recombination rates are from HapMap and 
gene annotations are from UCSC genome browser with build 35 coordinates. (C, right plot) 
Mean cotinine level (SE) according to rs2236709 genotypes (linear regression analysis: 
β=0.11, p=.5.0x10-4). MeanAA=6.35, SE=.72, n=1489; MeanAG=7.94, SE=1.18, n=900; and 
MeanGG=19.62, SE=4.86, n=151; post-hoc comparisons: AA vs AG, p=.843, R2=.0005, AA vs 
GG, p=3.67E-5, R2=.02 and AG vs GG, p=.001, R2=.013. 
 
Figure 3: (A) Expression of DRD2, TTC12 and ANKK1 in the human striatum across the 
lifetime. The x-axis represents different stages of fetal and postnatal development, as indicated. 
PCW=post-conception weeks, M=months, Y=years. (B) Striatal expression of DRD2 corrected 
for effects of developmental stage and stratified by rs2236709 genotypes. The dotted line 
visualizes the linear regression against the number of minor G-alleles (nAA=22, nAG=16 and, 
nGG=5). 
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Supplementary Material  
METHODS AND MATERIALS 
For all studies, informed consent had been obtained and ethical approval for the study was 
granted by the local Research Ethics committees.  
 
Assessment of self-reported smoking and definition of smoking categories in 
the four samples 
NFBC1966: At age 14, participants reported if they have ever smoked and how much via a 
postal questionnaire using eight options: 1) ‘Never’; 2) ‘I have tried once’; 3) ‘I have tried 
twice or more’; 4) ‘I smoke occasionally’; 5) ‘I smoke about twice a week’; 6) ‘I smoke 
between 1–5 cigarettes a day’; 7) ‘I smoke between 6–10 cigarettes a day’ and 8) ‘I smoke 
more than 10 cigarettes a day’.  
 The category Ever-Tried included groups 2-8; Smokers included groups 4-8; Weekly-
Smokers included groups 5-8, and Never-Tried included group 1.  
 
NFBC1986: At age 16, participants were asked by postal questionnaires: ‘Have you ever 
smoked or used snuff in your life?’ with four possible answers: 1) ‘no’,2) ‘yes but only 
tried’,3) ’yes, smoke’ and4) ’yes, snuff’.  
 Participants in group 1 were classified as Never-Tried; those in groups 2-3 were 
classified as Ever-Tried and those in group 3 as Smokers. Participants in group 4 (N=36) 
were excluded. Cohort members were also asked how often they smoked and participants 
who were smoking every week or more were classified as Weekly-Smokers. 
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ALSPAC: At age 15, participants were invited to attend a face-to-face interview about 
tobacco use. Participants were asked multiple questions including: ‘Have you ever tried a 
cigarette, even a puff?’. Participants who responded affirmatively to this question were 
classified as Ever-Tried and participants who answered ‘no’ were classified as Never-Tried. 
Participants who responded that they have smoked more than five cigarettes to the question 
’How many cigarettes have you smoked in your lifetime’ were classified as Smokers; those 
who responded that they smoked every week or more were classified as Weekly-Smokers. 
Please note that the study website contains details of all the data that is available 
through a fully searchable data dictionary (www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary). Ethical approval for the study was obtained from the ALSPAC ethics 
and Law Committee and the Local Research Ethics Committees. 
 
IMAGEN: Smoking use was assessed using the European School Survey Project on Alcohol 
and Drugs questionnaires (1). Participants were asked ‘On how many occasions during your 
lifetime have you smoked cigarettes?’. Seven options were given:  
‘0’,’1-2’,’3-5’,‘6-9’,‘10-19’, ‘20-39’ and ‘40 or more’.  
 Participants who responded zero were classified as Never-Tried and all the other as 
Ever-Tried. Participants who responded they have smoked more than five cigarettes were 
classified as Smokers. Participants were also asked how often they smoked and participants 
who were smoking every week or more frequently were classified as Weekly-Smokers. 
Although smoking behavior was assessed with different instruments in the four cohorts, the 
four categories were defined as similarly as possible.  
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Cotinine 
Approximately 80% of nicotine is metabolized to cotinine in the liver by CYP2A6 enzyme 
(2). Cotinine is a relatively stable compound whose level reflects the cumulative intake of 
nicotine in the last week (3). Cotinine was measured only in the ALSPAC cohort from 
plasma samples collected at 15 years using the Cozart Cotinine Enzyme Immunoassay. Data 
was taken from the ALSPAC from EDTA blood plasma samples taken in a clinic assessment 
at 15 years. The plasma samples were stored at -80 °C and allowed to thaw at room 
temperature before use. Cotinine was measured using the Cozart Cotinine Enzyme 
Immunoassay (EIA) serum kit (M155B1). All samples were run in duplicates. Absorbance 
was measured spectrophotometrically at a wave length of 450 nm. Cotinine concentrations 
are expressed as ng/ml of blood. Cotinine level was quintile-transformed to reach normality. 
Quintile transformation has the advantage of including individuals with cotinine level equal 
to zero such as non-smokers in the analyses (4). Analyses using log-transformation (that 
exclude non-smokers) were also performed and showed substantially identical results (data 
not shown). Cotinine level was available in 2540 participants who also had genetic data 
available and were of European ancestry. Linear regression was performed to investigate the 
association between plasma continine level and smoking (see Supplementary-Table-3).  
 
Genetic-association analyses within each sample 
NFBC1966: Genome-wide genotyping was performed using the Illumina Infinium 
370cnvDuo array. Quality control procedures used are described elsewhere (5). 33 directly 
genotyped SNPs covering the TTC12-ANKK1-DRD2 were available.  
NFBC1986: No genome-wide SNP data were available in this cohort. SNP rs2236709 was 
already genotyped as part of the custom Illumina Metabochip array (6). 13 additional SNPs 
were genotyped by Kbioscience (Hoddesdon, UK, http://www.kbioscience.co.uk/) using their 
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own system of fluorescence-based competitive allele-specific PCR (KASPar). SNPs were 
selected using a tagging approach to capture 75% of alleles at r2>=0.8.  
ALSPAC: Genome-wide genotyping was performed using the Illumina 550K array (Illumina, 
San Diego, CA, USA). We extracted the same SNPs available in NFBC1966.  
IMAGEN: Participants were genotyped using the Illumina Quad 610 and 660 arrays. Among 
the SNPs that passed quality controls, 29 of the 33 SNPs were available. 
 
Functional Magnetic Resonance Imaging (fMRI) 
Monetary incentive delay (MID) task (7): Each trial involved an anticipation phase (4 sec), a 
response phase (2 sec), a feedback phase (2 sec), and a fixation period (4 sec). During the 
anticipation phase, cues indicating the amount of reward that could be won in a given trial 
(large, small, or none) were shown for 4 seconds. The participant could win large or small 
numbers of points (10 or 2) by responding as quickly as possible to a response cue. The 
points were converted to food snacks (small chocolate candies) following testing (5 points 
per candy). The participant completed 22 trials per condition, yielding 66 trials in total. One 
cue (circle with two lines) signaled that a large reward could be won, another (circle with one 
line) that a small reward could be won, and a third cue (triangle) that no reward could be won 
in the respective trial. Following a random time interval, a response cue was displayed, and 
the participant was instructed to respond as quickly as possible to this cue by means of a 
button press. The time window in which responses were counted as "wins" was adjusted 
dynamically during the course of the experiment according to the participant's performance, 
such that on average the participant won in 66% of all trials. The response and feedback 
phases had a total duration of 2 seconds. Four seconds of inter-trial fixation periods separated 
the trials.  
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Data Acquisition: Structural and functional Magnetic Resonance Imaging (fMRI) data were 
acquired by using 3-T MRI scanners from a range of manufacturers (Siemens, Philips, 
General Electric, Bruker), and the scanning variables were specifically chosen to be 
compatible with all scanners (8). For the present task, 300 volumes were acquired for each 
participant. Each volume consisted of 40 slices aligned to the line connecting the anterior-
posterior commissure (2.4-mm thickness, 1-mm gap TR=2.20 s, TE=30 ms). The total 
scanning duration for the task took 11 min.  
 
fMRI Preprocessing and Analysis 
Structural and fMRI data were acquired using 3-T MRI scanners of different manufacturers 
(Siemens, GE, Philips). Pre-processing and data analyses were conducted using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) running in MATLAB® (9).  
First, echo-planar images were co-registered with the T1 structural image. Functional 
images were realigned and resliced to the first volume. We created a custom template from 
the T1 images of 552 adolescents by using the DARTEL toolbox (10) as implemented in 
SPM8. Single-subject contrast images were normalized to Montreal Neurological Institute 
(MNI) space by means of this custom template on the basis of the individual participants' 
DARTEL flow fields, and they were smoothed with a 5-mm Gaussian isotropic kernel. A 
first-level model was constructed on the unsmoothed single-participant data by using the 
following regressors: 1) anticipation of large reward, 2) anticipation of small reward, 3) 
anticipation of no reward, 4) feedback indicating large reward, 5) feedback indicating small 
reward, 6) feedback indicating no reward. Each regressor was included twice, once for 
successful trials, i.e., hits, and once for unsuccessful trials, i.e., misses. Trials in which 
participants failed to respond were modeled as separate error trials. Estimated movement 
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parameters were added to the design matrix in the form of 18 additional columns (3 
translations, 3 rotations, 3 quadratic and 3 cubic translations, and each 3 translations with a 
shift of ±1 TR).  
At the first level of analysis, changes in the blood-oxygen-level dependent (BOLD) 
response for each participant were assessed by linear combinations at the individual 
participant level, for each experimental condition; each trial (i.e. reward anticipation high 
reward) was convolved with the hemodynamic response function to form regressors that 
account for variance associated with the processing of reward anticipation and feedback. 
Contrast images of the parameter estimates were created for each participant.  
The normalized and smoothed single-subject contrast images were then taken to a 
second-level random effects analysis to identify brain regions activating by anticipation of 
reward. Gender, site of recruitment and handedness were used as covariates of no interest. 
For the present investigation, we focused on the analyses on the reward anticipation phase 
using the contrast ‘anticipation of large reward > anticipation of no reward’. 
Region of interest (ROI) analyses were run to investigate the association between 
activations in the main site of reward processing, i.e. the ventral striatum, and genotypes. The 
ROIs for the bilateral ventral striatum were extracted based on coordinates from previous 
findings (11) from the contrast ‘anticipation of high reward > anticipation of no reward’ as  
9-mm sphere (x= ±15, y=9, z=-9) using MarsBaR version 0.42 (12), see Supplementary-
Figure-2. 
From all participants who provided fMRI data for the MID task (n=1668), 1610 and 
1630 for the left and right ventral striatum, respectively, were left after outlier removal 
according to the following criterion: Mean +/- 2*SD. 1263 of these had genotypic data as 
well and these were included in the analyses between fMRI and genotypic data.  
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Genetic-association analyses within each sample:  
To control for population stratification, principal components were computed from genome-
wide data (NFBC1966, ALSPAC and IMAGEN) (13) or Multidimensional Scaling 
coordinates (14) computed using 130,000 SNPs from the Illumina metabochip array 
(NFBC1986) (6) and included as covariates into the analysis.  
 
Statistical Analyses 
Meta-analysis: The meta-analysis procedure in Plink v1.07 (15) requires input files with 
odds ratio, beta estimates, confidence interval, and p-value for each study. Meta-analysis 
outputs include a beta, odds ratios, and a p-value for fixed and random effect models. The 
fixed effects model assumes that the effect of the independent variable on the outcome is the 
same in each study. The random effect model allows the effect to vary between studies. The 
output gives two measures: Cochrane’s Q statistic and I2 heterogeneity index. The I2 statistic 
lies between 0%-100% with I2=0 indicating no heterogeneity (16).  
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TABLES 
Supplementary Table 1. Minor allele frequencies (MAF) in the 4 different cohorts. 
BP  Gene SNP Location 
MAF Ref allele/ N 
Overall Imagen Alspac 1966 1986 Other allele Samples Individuals 
112685412 TTC12 rs4517559 flanking 5’UTR 0.3736 0.3681 0.3586 0.4920 0.4944 C/T 4 8565 
112691986 TTC12 rs2236709 Intron 0.2588 0.2533 0.2396 0.2961 0.3031 G/A 4 8866 
112693407 TTC12 rs7927508 Intron 0.3667 0.3637 0.3578 0.4920 NA G/A 3 6336 
112694133 TTC12 rs2156486 Intron 0.1814 0.1817 0.2574 0.1865 0.1801 G/T 4 8569 
112699378 TTC12 rs723077 Coding, Met73Leu 0.4894 0.4955 0.4977 0.4260 NA C/A 3 6344 
112704356 TTC12 rs10502172 Intron 0.4596 0.4685 0.4851 0.4616 0.4526 T/C 4 8633 
112705919 TTC12 rs2303380 Intron splice site 0.3819 0.3824 0.3664 0.2970 NA G/A 3 6344 
112716539 TTC12 rs2288159 Intron 0.1561 0.1480 0.1479 0.2417 NA T/G 3 6343 
112721133 TTC12 rs4987094 Intron 0.1004 0.0977 0.0995 0.1979 NA A/G 3 6347 
112735810 TTC12 rs2276070 Intron 0.1541 0.1481 0.1478 0.2410 NA T/C 3 6345 
112739889 TTC12 rs719802 Intron 0.3953 0.3915 0.3970 0.3242 NA T/C 3 6344 
112739985 TTC12 rs719804 Intron 0.249 0.2500 0.1941 0.1732 NA G/A 3 6334 
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112749387 TTC12 rs2282511 flanking 3’UTR 0.3455 NA 0.3274 0.2957 0.2959 A/C 3 7145 
112754346 TTC12 rs754672 flanking 3’UTR 0.4894 0.4831 0.4621 0.4629 0.4513 T/C 4 8552 
112761718 ANKK1 rs877138 flanking 5’UTR 0.3431 0.3456 0.3336 0.3003 NA G/A 3 6347 
112768580 ANKK1 rs4590907 Intron 0.1436 0.1397 0.1362 0.2342 0.2487 G/T 4 8578 
112772031 ANKK1 rs7118900 Coding, Ala239Thr 0.1896 0.1870 0.1869 0.1565 NA A/G 3 6339 
112775225 ANKK1 rs4938016 Coding, Gly442Arg 0.44529 NA 0.3059 0.3775 0.0000 G/C 3 7239 
112775370 ANKK1 rs2734849 Coding, His490Arg 0.4886 0.4976 0.4925 0.4624 0.4750 G/A 4 8575 
112776038 ANKK1 rs1800497 
Coding, 
Glu713Lys,TaqI 
A 
0.2026 0.2015 0.1976 0.1703 0.1806 A/G 4 8561 
112788669 DRD2 rs6277 Coding, Pro219Pro 0.12201 NA 0.4505 0.4658 0.4537 A/G 3 7249 
112801119 DRD2 rs1076563 Intron 0.4127 0.4041 0.3924 0.4972 NA C/A 3 6346 
112815891 DRD2 rs7125415 Intron 0.09914 0.0944 0.0959 0.1896 NA T/C 3 6346 
112818599 DRD2 rs4648318 Intron 0.2538 0.2473 0.2439 0.3407 NA C/T 3 6346 
112824662 DRD2 rs4274224 Intron 0.4823 0.4814 0.4917 0.2391 NA G/A 3 6342 
112829684 DRD2 rs4581480 Intron 0.09919 0.0954 0.1027 0.0683 NA C/T 3 6344 
112834984 DRD2 rs7131056 Intron 0.4205 0.4202 0.4264 0.4942 NA C/A 3 6341 
112846601 DRD2 rs4938019 Intron 0.1447 0.1441 0.1401 0.2335 0.2392 C/T 4 6334 
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112852165 DRD2 rs12364283 flanking 5’UTR 0.07563 0.0779 0.0775 0.0787 NA G/A 3 8583 
112857971 DRD2 rs10891556 intergenic 0.1758 0.1751 0.1734 0.2380 NA T/G 3 6339 
112860946 DRD2 rs6589377 intergenic 0.3776 NA 0.3820 0.1689 NA G/A 4 6345 
112863421 DRD2 rs4482060 intergenic 0.30032 NA 0.4330 0.2589 0.2545 T/A 3 8576 
 
 
Supplementary Table 2. Association between SNPs spanning the TTC12-ANKK1-DRD2 gene-cluster and self-reported smoking behavior for 
Smokers vs Never-Tried.  
Notes: Smokers (N=2819) are compared Never-Tried (N=6049) (binary logistic regression). Results from NFBC1966, NFBC1986, IMAGEN 
and ALSPAC are combined using meta-analysis. FEM=Fixed effect model, REM=Random effect model, Q=Cochrane’s Q statistic, 
I2=heterogeneity index (0-100). Significant p values are in bold, of these those that remain significant after Bonferroni correction for multiple 
testing are indicated by an asterisk. Thick lines indicate LD blocks. 
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BP  Gene SNP Location MAF 
Ref 
allele/ 
N P OR 
Q I2 
Other 
allele 
Samples Individuals (FEM) (REM) (FEM) (REM) 
112685412 TTC12 rs4517559 flanking 5’UTR 0.3736 C/T 4 8565 0.01   1.09   0.26 25 
112691986 TTC12 rs2236709 Intron 0.2588 G/A 4 8866 0.001*   1.13   0.46 0 
112693407 TTC12 rs7927508 Intron 0.3667 G/A 3 6336 0.008   1.12   0.26 25.84 
112694133 TTC12 rs2156486 Intron 0.1814 G/T 4 8569 0.022   0.9   0.46 0 
112699378 TTC12 rs723077 
Coding, 
Met73Leu 0.4894 C/A 3 6344 0.3   0.96   0.39 0 
112704356 TTC12 rs10502172 Intron 0.4596 T/C 4 8633   0.14   0.9 0.01 76.24 
112705919 TTC12 rs2303380 
Intron splice 
site 0.3819 G/A 3 6344   0.83   1.02 0.001 84.44 
112716539 TTC12 rs2288159 Intron 0.1561 T/G 3 6343 0.009   1.14   0.86 0 
112721133 TTC12 rs4987094 Intron 0.1004 A/G 3 6347 0.013   1.16   0.94 0 
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112735810 TTC12 rs2276070 Intron 0.1541 T/C 3 6345 0.009   1.16   0.81 0 
112739889 TTC12 rs719802 Intron 0.3953 T/C 3 6344 0.21 0.66 1.05 1.04 0.011 77.98 
112739985 TTC12 rs719804 Intron 0.249 G/A 3 6334 0.09   1.09   0.19 39.05 
112749387 TTC12 rs2282511 flanking 3’UTR 0.3455 A/C 3 7145   0.19   1.11 0.01 77.25 
112754346 TTC12 rs754672 flanking 3’UTR 0.4894 T/C 4 8552   0.07   0.89 0.02 68.26 
112761718 ANKK1 rs877138 flanking 5’UTR 0.3431 G/A 3 6347   0.65   1.05 0.004 81.87 
112768580 ANKK1 rs4590907 Intron 0.1436 G/T 4 8578 0.05   1.08   0.43 0 
112772031 ANKK1 rs7118900 
Coding, 
Ala239Thr 0.1896 A/G 3 6339 0.78   0.99   0.58 0 
112775225 ANKK1 rs4938016 
Coding, 
Gly442Arg 0.44529 G/C 3 7239   0.06   1.12 0.08 61.34 
112775370 ANKK1 rs2734849 
Coding, 
His490Arg 0.4886 G/A 4 8575   0.09   0.9 0.03 66.72 
112776038 ANKK1 rs1800497 
Coding, 
Glu713Lys,TaqI 0.2026 A/G 4 8561 0.85   1.01   0.72 0 
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A 
112788669 DRD2 rs6277 
Coding, 
Pro219Pro 0.12201 A/G 3 7249   0.03   0.89 0.09 59.03 
112801119 DRD2 rs1076563 Intron 0.4127 C/A 3 6346 0.003   0.89   0.14 48.44 
112815891 DRD2 rs7125415 Intron 0.09914 T/C 3 6346 0.01   1.16   0.77 0 
112818599 DRD2 rs4648318 Intron 0.2538 C/T 3 6346 0.003   1.14   0.18 41.98 
112824662 DRD2 rs4274224 Intron 0.4823 G/A 3 6342 0.93   1   0.14 49.82 
112829684 DRD2 rs4581480 Intron 0.09919 C/T 3 6344   0.53   1.07 0.1 56.29 
112834984 DRD2 rs7131056 Intron 0.4205 C/A 3 6341 0.22   1.05   0.31 15.05 
112846601 DRD2 rs4938019 Intron 0.1447 C/T 4 6334 0.09   1.08   0.52 0 
112852165 DRD2 rs12364283 flanking 5’UTR 0.07563 G/A 3 8583 0.88   1.01   0.88 0 
112857971 DRD2 rs10891556 intergenic 0.1758 T/G 3 6339 0.51   1.03   0.38 0 
112860946 DRD2 rs6589377 intergenic 0.3776 G/A 4 6345   0.86   1.01 0.06 59.84 
112863421 DRD2 rs4482060 intergenic 0.30032 T/A 3 8576 0.68   1.02   0.14 48.38 
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Supplementary Table 3. Association between SNPs spanning the TTC12-ANKK1-DRD2 gene-cluster and self-reported smoking behavior for 
Weekly-Smokers vs Never-Tried.  
Notes: Weekly-Smokers (N=1624) are compared to Never-Tried (N=6049) (binary logistic regression). Results from NFBC1966, ALSPAC, 
NFBC1986, and IMAGEN are combined using meta-analysis. FEM=Fixed effect model, REM=Random effect model, Q=Cochrane’s Q statistic, 
I2=heterogeneity index (0-100). Significant p values are in bold (uncorrected, Bonferroni corrected threshold: 0.0015 are indicated by *). Thick 
lines indicate LD blocks.  
 
BP  Gene SNP Location MAF 
Ref/ N P OR 
Q I2 Other 
allele 
Samples Individuals (FEM) (REM) (FEM) (REM) 
112685412 TTC12 rs4517559 
flanking 
5’UTR 0.3736 C/T 4 7385 0.04   1.09   0.72 0 
112691986 TTC12 rs2236709 Intron 0.2588 G/A 4 7672 0.001*   1.16   0.94 0 
112693407 TTC12 rs7927508 Intron 0.3667 G/A 3 5281 0.05   1.12   0.62 0 
112694133 TTC12 rs2156486 Intron 0.1814 G/T 4 7390 0.04   0.89   0.61 0 
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112699378 TTC12 rs723077 
Coding, 
Met73Leu 0.4894 C/A 3 5287 0.45   0.96   0.43 0 
112704356 TTC12 rs10502172 Intron 0.4596 T/C 4 7456   0.08   0.89 0.08 56.11 
112705919 TTC12 rs2303380 
Intron 
splice site 0.3819 G/A 3 5288   0.63   1.06 0.03 72.38 
112716539 TTC12 rs2288159 Intron 0.1561 T/G 3 5286 0.11   1.12   0.96 0 
112721133 TTC12 rs4987094 Intron 0.1004 A/G 3 5290 0.09   1.15   0.8 0 
112735810 TTC12 rs2276070 Intron 0.1541 T/C 3 5289 0.11   1.12   0.97 0 
112739889 TTC12 rs719802 Intron 0.3953 T/C 3 5289   0.43   1.07 0.12 52.08 
112739985 TTC12 rs719804 Intron 0.249 G/A 3 5278   0.22   1.14 0.12 53.62 
112749387 TTC12 rs2282511 
flanking 
3’UTR 0.3455 A/C 3 6077   0.07   1.14 0.12 52.19 
112754346 TTC12 rs754672 
flanking 
3’UTR 0.4894 T/C 4 7377 0.008   0.89   0.13 46.17 
112761718 ANKK1 rs877138 
flanking 
5’UTR 0.3431 G/A 3 5290   0.46   1.08 0.08 60.56 
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112768580 ANKK1 rs4590907 Intron 0.1436 G/T 4 7398 0.41   1.04   0.79 0 
112772031 ANKK1 rs7118900 
Coding, 
Ala239Thr 0.1896 A/G 3 5283 0.84   0.99   0.7 0 
112775225 ANKK1 rs4938016 
Coding, 
Gly442Arg 0.44529 G/C 3 6153 0.01   1.12   0.14 48.79 
112775370 ANKK1 rs2734849 
Coding, 
His490Arg 0.4886 G/A 4 7397 0.005   0.89   0.34 10.17 
112776038 ANKK1 rs1800497 
Coding, 
Glu713Lys 0.2026 A/G 4 7386 0.65   1.02   0.82 0 
112788669 DRD2 rs6277 
Coding, 
Pro219Pro 0.12201 A/G 3 6161 0.005   0.88   0.39 0 
112801119 DRD2 rs1076563 Intron 0.4127 C/A 3 5289 0.03   0.88   0.55 0 
112803549 DRD2 rs2471857 Intron 0.1577 T/C 3 5289 0.91   1.01   0.54 0 
112815891 DRD2 rs7125415 Intron 0.09914 T/C 3 5289 0.24   1.1   0.91 0 
112818599 DRD2 rs4648318 Intron 0.2538 C/T 3 5286 0.02   1.16   0.32 11.96 
112824662 DRD2 rs4274224 Intron 0.4823 G/A 3 5287 0.85   0.99   0.45 0 
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112829684 DRD2 rs4581480 Intron 0.09919 C/T 3 5284   0.87   1.03 0.09 57.52 
112834984 DRD2 rs7131056 Intron 0.4205 C/A 3 5280 0.09   1.1   0.61 0 
112846601 DRD2 rs4938019 Intron 0.1447 C/T 4 7404 0.06   1.1   0.99 0 
112852165 DRD2 rs12364283 
flanking 
5’UTR 0.07563 G/A 3 5283 0.63   1.05   0.22 34.83 
112857971 DRD2 rs10891556 intergenic 0.1758 T/G 3 5289 0.26   1.09   0.83 0 
112860946 DRD2 rs6589377 intergenic 0.3776 G/A 4 7396 0.58   1.03   0.51 0 
112863421 DRD2 rs4482060 intergenic 0.30032 T/A 3 6148 0.18   1.07   0.466 0 
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Supplementary Table 4. Association between SNPs spanning the TTC12-ANKK1-DRD2 
gene-cluster and cotinine level (quantile-transformed in the ALSPAC cohort (N=2,540) 
(linear regression). Significant p values are in bold (uncorrected, Bonferroni corrected 
threshold: 0.0015 are indicated by *). Thick lines indicate LD blocks. 
SNP  Gene BP Location MAF 
Ref 
allele/  
BETA STAT p 
Other 
allele 
rs4517559 TTC12 1.1E+08 
flanking 
5’UTR 
0.3736 C/T 0.09 3.18 0.001* 
rs2236709 TTC12 1.1E+08 Intron 0.2588 G/A 0.11 3.49 0.0005* 
rs7927508 TTC12 1.1E+08 Intron 0.3667 G/A 0.09 3.16 0.002 
rs2156486 TTC12 1.1E+08 Intron 0.1814 G/T 0.03 0.82 0.41 
rs723077 TTC12 1.1E+08 
Coding, 
Met73Leu 
0.4894 C/A -0.03 -1.2 0.23 
rs10502172 TTC12 1.1E+08 Intron 0.4596 T/C -0.01 -0.36 0.72 
rs2303380 TTC12 1.1E+08 
Intron splice 
site 
0.3819 G/A -0.02 -0.77 0.49 
rs2288159 TTC12 1.1E+08 Intron 0.1561 T/G 0.06 1.58 0.11 
rs4987094 TTC12 1.1E+08 Intron 0.1004 A/G 0.04 0.82 0.41 
rs2276070 TTC12 1.1E+08 Intron 0.1541 T/C 0.06 1.57 0.12 
rs719802 TTC12 1.1E+08 Intron 0.3953 T/C -0.01 -0.29 0.78 
rs719804 TTC12 1.1E+08 Intron 0.249 G/A -0.01 -0.4 0.69 
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rs2282511 TTC12 1.1E+08 
flanking 
3’UTR 
0.3455 A/C 0 0.15 0.88 
rs754672 TTC12 1.1E+08 
flanking 
3’UTR 
0.4894 T/C -0.03 -1.19 0.23 
rs877138 ANKK1 1.1E+08 
flanking 
5’UTR 
0.3431 G/A 0.01 0.35 0.73 
rs4590907 ANKK1 1.1E+08 Intron 0.1436 G/T 0.07 1.7 0.09 
rs7118900 ANKK1 1.1E+08 
Coding, 
Ala239Thr 
0.1896 A/G -0.05 -1.36 0.18 
rs4938016 ANKK1 1.1E+08 
Coding, 
Gly442Arg 
0.44529 G/C 0.07 2.34 0.02 
rs2734849 ANKK1 1.1E+08 
Coding, 
His490Arg 
0.4886 G/A -0.03 -1.17 0.24 
rs1800497 ANKK1 1.1E+08 
Coding, 
Glu713Lys, 
TaqI A 
0.2026 A/G -0.04 -0.98 0.33 
rs6277 DRD2 1.1E+08 
Coding, 
Pro219Pro 
0.12201 A/G -0.05 -1.81 0.07 
rs1076563 DRD2 1.1E+08 Intron 0.4127 C/A -0.05 -1.64 0.1 
rs2471857 DRD2 1.1E+08 Intron 0.1577 T/C -0.02 -0.42 0.67 
rs7125415 DRD2 1.1E+08 Intron 0.09914 T/C 0.07 1.45 0.15 
rs4648318 DRD2 1.1E+08 Intron 0.2538 C/T 0.06 1.97 0.05 
rs4274224 DRD2 1.1E+08 Intron 0.4823 G/A -0.03 -1.03 0.3 
rs4581480 DRD2 1.1E+08 Intron 0.09919 C/T -0.01 -0.2 0.84 
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rs7131056 DRD2 1.1E+08 Intron 0.4205 C/A 0 -0.07 0.94 
rs4938019 DRD2 1.1E+08 Intron 0.1447 C/T 0.05 1.36 0.17 
rs12364283 DRD2 1.1E+08 
flanking 
5’UTR 
0.07563 G/A 0.05 0.87 0.38 
rs10891556 DRD2 1.1E+08 intergenic 0.1758 T/G 0.04 1.06 0.29 
rs6589377 DRD2 1.1E+08 intergenic 0.3776 G/A -0.04 -1.24 0.22 
rs4482060 DRD2 1.1E+08 intergenic 0.30032 T/A -0.03 -1.01 0.31 
 
 
 
FIGURE LEGENDS: 
Supplementary-Figure 1: Linkage disequilibrium (LD) of the chromosome 11q23 region in 
the NFBC1966 (A), ALSPAC (B), IMAGEN (C) and NFBC1986 (D) cohorts. Three 
haplotype blocks are indicated with borders. LD is coded according to the following color 
scheme: LOD < 2 and D’ < 1: white; LOD < 2 and D’ = 1: blue; LOD ≥ 2 and D’ < 1: shades 
of red; LOD ≥ 2 and D’ = 1: bright red. The TTC12-ANKK1-DRD2 gene-cluster covers a 
large genomic area (chromosome 11 TTC12: 112,690,539-112,749,226, 58,688 bp; ANKK1: 
112,763,723-112,776,350, 12,628 bp; DRD2 short isoform: 112,785,528-112,851,103, 
12,628 bp and DRD2 long isoform: 112,785,528-112,851,103, 65,576 bp). 
 
Supplementary-Figure 2: (A) Box plot of blood-oxygen level-dependent (BOLD) response 
in left ventral striatum stratified by rs2236709 genotype (note that G-carriers are pooled 
together). The x-axis represents the number of minor G-alleles (NAA=706, NAG/GG=557). 
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Mean BOLD response within each group was as follows: MAA=0.365, SDAA=0.370 and 
MAG/GG=0.417, SDAG/GG=0.391. (B) Region of interest as extracted from the contrast 
‘anticipation of high reward > anticipation for no reward’ from the modified Monetary 
Incentive Delay (MID) task in the IMAGEN sample (N=1263) indicating left and right 
ventral striatum centred at Montreal Neurological Institute (MNI): x=±15, y=9, z=-9.  
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